Paper Details

  1. Home
  2. Paper Details

High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis.

Author: AzimH A, BociekR G, GandiniS, MalekR A, SantoroL

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This study discusses the standard chemotherapy regimen for aggressive non-Hodgkin's lymphoma (NHL), which includes cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). It highlights the importance of rituximab in treating B-cell NHL but also discusses the limitations of access to rituximab due to cost.
Paper Details　
Original Abstract of the Article :
Aggressive non-Hodgkin's lymphoma (NHL) represents approximately 60% of lymphomas in the West and even more in the developing world. cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is recognized as the standard chemotherapy regimen and the addition of rituximab to B-cell subtypes ha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/annonc/mdp425

データ提供：米国国立医学図書館（NLM）

Dose Intensity: A Key to Success in Aggressive Non-Hodgkin's Lymphoma

Aggressive non-Hodgkin's lymphoma is a serious disease, and finding the right treatment is crucial. This research is like a camel caravan searching for the most effective path through the desert of cancer treatment. The researchers reviewed studies on the use of high-dose intensity doxorubicin in treating aggressive non-Hodgkin's lymphoma. They found that the dose intensity of doxorubicin was a significant factor in determining patient survival. This research emphasizes the importance of optimizing treatment regimens to achieve the best possible outcomes.

Optimizing Chemotherapy for Lymphoma

The study highlights the importance of dose intensity in chemotherapy regimens for aggressive non-Hodgkin's lymphoma. This emphasizes the need for careful planning and monitoring to ensure that patients receive the optimal dose of medication for the best possible chance of recovery.

A Camel's Perspective on Lymphoma

As a camel, I know that survival in the desert requires resilience and resourcefulness. Lymphoma, like a relentless sandstorm, can be challenging to overcome. This research underscores the importance of understanding the nuances of treatment and finding the best ways to combat this disease.

Dr.Camel's Conclusion

The review highlights the importance of dose intensity as a key factor in determining survival outcomes for patients with aggressive non-Hodgkin's lymphoma. This underscores the need for careful optimization of treatment regimens to maximize effectiveness and minimize side effects.

Date :
  1. Date Completed 2010-08-17
  2. Date Revised 2020-02-03
Further Info :

Pubmed ID

19850640

DOI: Digital Object Identifier

10.1093/annonc/mdp425

Related Literature

Article Analysis
・Effective treatment of lymphoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.